Member Info for PM2022

Great post from Porky reposted for newbies.

The more I research this Biotech the more I like it.

I fully accept there has been past disappointment mainly driven by shareholder dilution from fund raising. Not to mention that there is always uncertainty when a new management team takes over, but I have to say the work they are doing is bloody phenomenal, no other words to describe it.

For me to invest, I must like the company and what they do, like the management team behind it and from an investment case I need to see a high growth opportunity with a Share Price below its underlying value. With Valirx it fully meets all my criteria.

Tonight, we sit at an Mcap of £ 15.7m and a Share price of 24.5p BUT we only have 65m of shares in issue, so it doesn’t take much buying to really move the share price.

Now I follow SP Angel, they are also house broker to another stock I’m heavily backing, and I rate this broker. Now in some notes I read from them they state that the group’s market capitalisation is far less than its peer-group median, which stands at £ 52.1 million, and they consider this price discrepancy is unjustified, considering the two clinical stage drugs and its pre-clinical programme.

So, even at a Share price of 80p it would only be at the market average for this position. IMO the stock is clearly unloved and has been lacking support and coupled by the dilution and management uncertainty Is why it’s been just coasting flat at these levels.

Now I accept there has been a previous false dawn when it was rumoured a deal might be imminent and the share price rallied to 73p and this has also added to investor concerns but, its hardly surprising with a share price this low and the upside potential so high if a deal is struck.

Sareum Holdings (SAR) as a direct comparison is currently at £ 237 mcap that is 15 times our closing price tonight and the main difference is validation. IF Suzy can get a license deal over the line, it will be a “Transformative Year” and I now believe this is what the company means.

Further research showed me that even the smallest license deals are around £ 40m with royalties. Valirx have two on the brink of signing. So, in my considered opinion my price target here of £ 2 (£130m mcap) probably needs revising upwards in line with SAR i.e., £ 3.60

WE will see how events unfold, I fully accept the downside risk of another placement end of Q1 but fair value 80p without a deal and upside to £ 3.60 with deals looks like a cracking risk/reward ratio to me and they have enough cash and time to secure a licensing deal before we need to worry about a further raise and dilution.

As market awareness to Valirx increases I believe the Share Price will climb. We are starting to see that now and these next few weeks could prove to be material to the companies position on the world stage and its associated value.

For the above reasons I’m feeling very positive here and that’s why I’m adding to my positio

All comes down to the valuation of the company. VAL market cap only 15 million and should be on the way up if not now then very soon but it has huge potential.

I am 90% that Suzy will get a deal this year and very likely in the next few days or by the end of September. That will be transformational at this market cap.

I don't like investing in companies valued at 300 million odd because for it to go up even 10% that would be an extra 30 million market cap which is double the value of VAL. VAL has an easy gap up lined up for me. Val should go up and other over inflated companies will be on the way down.

Go and invest in SAR then if you think so highly of it and see how far you get pal.

As for VAL a great CEO in charge now doing a real job. Bottom line lots to happen in the coming weeks/ months with a market cap of only 15 million. It is the best opportunity I have ever come across. Really looking forward to a deal that will change VAL forever.

Rahel may be best you do some serious research before posting.

Val has only gone up few pennies market cap still only 15 million. Buying opportunity for all given how big a standard deal is likely to be. Timelines and volume this week all indicate news coming very soon which could be followed by a second or even a third deal. All to play for here.

A great week.

I do not believe in anyway this is a pump. News of a deal is due and we know Suzy has been actively been looking for a deal for all three drugs. 201 is a great drug with little side effects. Our market cap is still only 15 million despite having 2 phase 2 drugs and a very promising 301 which is likely to be out licensed soon as well.

The great part is that we have been so undervalued that you can carry buying this for a very long time until it reaches £s before it is even considered par value if it was to get a decent deal. Therefore it is just simply a tiny rerate and next week we will attack 35p and onwards. A deal should easily take us to the £s but if no deal then eventually could fall but all the signs throughout the year are very promising and the time has now arrived. Upside is massive compared to downside at this market cap.

This should follow the same trend as SAR because after the first deal the sentiment will change and could possibly get a second and third deal shortly afterwards, PYC update and new drugs being added into our portfolio. Therefore expect this upward trend to continue in general for the next few years.

News due and supported by strong buys. Here are my notes for newcomers.

1) Live Q and A they were very confident they would get a deal from list of interested parties that was more than 3 months ago.
2) Interview posted last week Suzy seemed confident and stated the drugs ARE being out licensed.
3) Transformational year.
4) PYC work was completed a few months ago for 201.
5) Silence from Suzy.
6) Market cap only 14 millions.
7) Any deal will likely involve huge upfront payments, Milestone payments and royalties worth many millions. Therefore should multibag based on current market cap.
8) PYC on board of directors for VAL. They would have done research and would have been aware of previous interest for the drugs before committing to a deal involving only 6 percent of deal payment.
9) Some great investors in this stock from the industry giving us further confidence.
10) Cash in bank until early next year therefore deal is needed very soon.

Get a deal and £1-£2 plus on the cards and could be followed by a second deal or even a third. TIME TO LOAD UP. THE NEW SAR IS ARRIVING.

Come last hour could we even hit 30 today. News is fast approaching and great part is our market cap is still peanuts and will be until we reach £s given the potential size of any deal.

3 great drugs all lined up, which will get over the line first. 201 has to be the favourite. Never seen a chance like this before on AIM.

It is clear news is about to come. Market cap still only 14 million. One deal and will likely several bag. What a chance this is.

Could be the last call today. Could RNS drop Monday morning or next week. Last hour of the day will be interesting.

We were in that trading range 2 months ago 19p-22p. This time it is due to anticipation of partnership news. Current events are independent of past events and news for 201 partnership is fast approaching.

Should be a nice big blue day tomorrow leading into Monday. As they say you do not want to be out of this over the weekend.

It's very positive that the price has held up today. Like last years move from 8p to 74p it went up a few pennies then stabilized then took another leg up. This time with a deal it will stay up.

I think if we can settle in the 30-35p range before partnership RNS that would be fantastic. We can then move forward and wait for the second partnership RNS with plenty of news due after the first RNS ranging from possible second and third deal, new pipeline RNSs, operational updates regarding work carried out by PYC and the list goes on all likely before Christmas.

If this works out could be several pounds with some cash payment to VAl therefore no cash raise either. In it to win it.

I also see a crook when I see one and Suzy is not one. If she wanted to speculate we would be 100p before a deal but the small hints come from careful analysis.

We will not be at a 13 million market cap once the RNS comes out. You pay the price and you take the chance the difference is in the research you do and for me this level is a buying level but more risky than when the RNS comes out.

Although timeline of a deal is speculation I suspect it is based on a number of events of happening. PYC had completed the work for Val 201 first and that was now a few months ago. Val made is clear it was a key priority to get a partner for VAl 201 which was why it was done first. Also watching the most recent interview Suzy suggests she must have some cash coming through given her plans of having 4 drugs a year coming through and the general feel of that interview suggests a deal is coming very soon.

Small hints are given in the Q and A if one has been doing the research and then we had a large number of trades going through yesterday. Val also cannot afford to keep waiting and PYC need payment. It would therefore be reasonable to suggest a timeline for August/September for the first deal and is not a random guess.

Regardless upside is far greater than the downside if one is patient and the forward momentum should continue after the first deal.

I am going for RNS Monday so expect significant rise today and tomorrow. But if that fails then it is a hold until news at this cheap market cap because news is coming as far as I am concerned.

Steady rise into and during September if no news until it drops.

Lots of hints if you have been following over the last year but they are very cautious. All points to very big news coming very soon. Most recent hint the new drugs that are being lined up which requires cash.

You pay the price at a low market cap and take your chance and be patient. Any deal will be transformational and this stock will open at a new price and it will be very hard to buy. Good time to buy for sure given risk to reward ratio.

Key is to break 22p today. I suspect we will head up in September as many predict a deal during that month but I am going for an RNS next week. Getting very close.

I must also add that the purpose of that interview was to bring in new drugs into Val and was aimed at academics. Suzy spoke of bringing in 3/4 drugs a year forever and was actively searching.

To me that was a very positive sign that we will shortly get a deal with cash payment otherwise hard to plan ahead in such a way. Lots of clues and a brilliant entry point. I think Val will be like SAR but you will just have to hold it.

Porky your a smart investor.

I totally agree it has crossed my mind why would Val not get taken over. But I have watching all the interviews carefully and it appears the drugs are being out licensed. Most recent one I posted last week where Suzy stated the drugs are being out licensed. Even if Val would get taken over despite the share price one would imagine it would not be for less than 120-150p at the very least.

Great potential here for sure with drugs being lined up at such a low market cap.

It is different this time with Suzy as CEO and the work done by Physiomics. Also I have picked up many hints along the way and I trust this board.

Anyway to an extent if you wish to multibag in this game it is to a game of speculation to accumulate backed up strong research. Nothing is a given but upside here is massive. Stick to my strong buy and a deal soon but we will soon find out.

The facts are that we are undervalued with proven drugs. With two phase 2 drugs and Val 301 a market cap of 13 million is very low. Throw in all the work by PYC as well and would they do all that for free if they thought it is worthless. Please also see broker report which backs up our low valuation.

A deal will significantly increase our market cap. Whether that happens or not is for others to judge but I have done my research and all looking good here. A deal to land very soon.

Totally agree. You pay the price if you want to enter after a deal then fine. But know that the gap up is likely to be significant for a first deal and you will find it hard to buy in.

Do the research and buy in or wait. Simple. For me I have been following all year and it is a buy now.